EMD Serono Appoints New Leaders - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

EMD Serono Appoints New Leaders

EMD Serono, a subsidiary of Merck KGaA, reported the appointments of Gary Zieziula as COO, Allene Diaz as senior vice-president of Managed Markets, Lisa Buffington as vice-president of US Communications, Alexander Kuta as vice-president and head of US Regulatory Affairs, and Michael Ruggiero as vice-president of US Government Affairs and Policy.

Zieziula is responsible for increasing the growth of the US organization by controlling the performance of EMD franchises.

Diaz is responsible for developing and executing Managed Markets marketing, sales, and contracting strategies for EMD Seronoproducts.

Buffington is responsible for executing all aspects of the company’s communications strategy, including external and employee communications, media relations, corporate reputation, product communications, community relations, as well as meetings and events.

Kuta is responsible for the strategic direction of EMD Serono’s regulatory efforts with the FDA, overseeing regulatory submissions in the US and strengthening interactions with the FDA.

Ruggiero is responsible for federal and state legislative, policy, political, and advocacy strategy and execution for EMD Serono’s business.

Source: EMD Serono


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here